Evidence map›Paper›PMID 28238698›Full record

ArticleEBioMedicine2017

Nasopharyngeal Protein Biomarkers of Acute Respiratory Virus Infection.

Thomas W Burke, Ricardo Henao, Erik Soderblom, Ephraim L Tsalik, J Will Thompson, Micah T McClain, Marshall Nichols, Bradly P Nicholson, Timothy Veldman, Joseph E Lucas and 6 more

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Clinical and Virological Characteristics of Acute Sinusitis in Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Thomas W BurkeCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA.
Ricardo HenaoCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA; Department of Electrical and Computer Engineering, Duke University, Durham, NC 27708, USA.
Erik SoderblomProteomics and Metabolomics Shared Resource, Duke University Medical Center, Durham, NC 27708, USA.
Ephraim L TsalikCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA; Durham Veteran's Affairs Medical Center, Durham, NC 27705, USA; Division of Infectious Diseases and International Health, Department of Medicine, Duke University, Durham, NC 27710, USA.
J Will ThompsonProteomics and Metabolomics Shared Resource, Duke University Medical Center, Durham, NC 27708, USA.
Micah T McClainCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA; Division of Infectious Diseases and International Health, Department of Medicine, Duke University, Durham, NC 27710, USA; Section for Infectious Diseases, Medicine Service, Durham Veteran's Affairs Medical Center, Durham, NC 27705, USA.
Marshall NicholsCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA.
Bradly P NicholsonDurham Veteran's Affairs Medical Center, Durham, NC 27705, USA.
Timothy VeldmanCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA.
Joseph E LucasCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA; Department of Electrical and Computer Engineering, Duke University, Durham, NC 27708, USA.
M Arthur MoseleyCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA; Proteomics and Metabolomics Shared Resource, Duke University Medical Center, Durham, NC 27708, USA.
Ronald B TurnerSchool of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Robert Lambkin-WilliamshVIVO, London, United Kingdom.
Alfred O HeroDepartment of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI 48109, USA.
Christopher W WoodsCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA; Division of Infectious Diseases and International Health, Department of Medicine, Duke University, Durham, NC 27710, USA; Section for Infectious Diseases, Medicine Service, Durham Veteran's Affairs Medical Center, Durham, NC 27705, USA. Electronic address: chris.woods@duke.edu.
Geoffrey S GinsburgCenter for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27708, USA. Electronic address: geoffrey.ginsburg@duke.edu.
Duke University · USDurham VA Medical Center · UShVIVO (United Kingdom) · GBUniversity of Michigan · USUniversity of Virginia · US

Funding

Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI Sarah B. Peskoe · 2006 to 2026
$24.6M
NIA NIH HHS P30 AG028716
6 · The paper itself

Abstract

Infection of respiratory mucosa with viral pathogens triggers complex immunologic events in the affected host. We sought to characterize this response through proteomic analysis of nasopharyngeal lavage in human subjects experimentally challenged with influenza A/H3N2 or human rhinovirus, and to develop targeted assays measuring peptides involved in this host response allowing classification of acute respiratory virus infection. Unbiased proteomic discovery analysis identified 3285 peptides corresponding to 438 unique proteins, and revealed that infection with H3N2 induces significant alterations in protein expression. These include proteins involved in acute inflammatory response, innate immune response, and the complement cascade. These data provide insights into the nature of the biological response to viral infection of the upper respiratory tract, and the proteins that are dysregulated by viral infection form the basis of signature that accurately classifies the infected state. Verification of this signature using targeted mass spectrometry in independent cohorts of subjects challenged with influenza or rhinovirus demonstrates that it performs with high accuracy (0.8623 AUROC, 75% TPR, 97.46% TNR). With further development as a clinical diagnostic, this signature may have utility in rapid screening for emerging infections, avoidance of inappropriate antibacterial therapy, and more rapid implementation of appropriate therapeutic and public health strategies.

Indexed as

BiomarkersHumansInfluenza A Virus, H3N2 SubtypeInfluenza, HumanMass SpectrometryProteomeRespiratory MucosaRhinovirusBiomarkersProteomeDiagnostic biomarkerHuman rhinovirusInfectious diseaseInfluenzaProteomics

Identifiers

PMID28238698
PMCPMC5360578
OpenAlexW2589148390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.